SA.41471(2015/X) Purpose of public aid: Article 25 of Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty That’s it. EU L 187/1 of 26.06.2014).The aim of the project is to develop and implement a candidate for the drug &ndash into the activities of Ryvu Therapeutics S.A.; CDK8/19 kinase inhibitor for the treatment of solid tumours. It will be characterised in clinical phase I/II (up to the first stage of phase II of the dose expansion), providing an opportunity for more effective and safer treatment of cancer patients who have exhausted the possibilities of current therapy. The GMP medicinal product used, its specification, formulation and PK profile are the same as the current wedge used in the ongoing study. AML/MDS (FDA Report). The candidate is characterised by a beneficial oral route of administration in capsules and can be used as monotherapy or in combination with chemotherapy, targeted therapies and immunotherapy. The strategy involves work on identifying the most promising therapeutic indications (e.g. trinegative breast cancer or prostate cancer). It is planned to identify and develop methods for measuring the effectiveness of PD and sensitivity markers in the wedge test. As part of phase I/II clinical trials, oncological patients will have an initial assessment of the therapeutic potential for selected indications. It is planned to measure PD markers, which in combination with the PK profile and safety will help in defining the recommended dose for further testing. The strategy assumes parallel work on breast cancers and three other types of cancer to increase the chance of selecting a drug candidate with the highest therapeutic potential in a given type of tumor, and thus the best chances of obtaining effective and targeted therapy, competitive advantage and increased chances of commercialisation.